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Abstract 
The prefrontal cortex (PFC) has attracted great research interest because of its 
involvement in the control of executive functions in both health and disease, and 
particularly in cognitive functions such as working memory. In schizophrenia, 
alterations in the PFC are documented at many different levels: molecular, cellular 
and functional. Furthermore, deficits in cognitive abilities are considered a core 
feature of schizophrenia and remain a major unmet medical need with respect to this 
disorder. In order to understand the sites of action of currently-used drugs, as well as 
of the new experimental treatments being developed and acting in this brain region, it 
is important to have detailed knowledge of the corresponding chemical 
neuroanatomy. Here we review current knowledge regarding the cellular localization 
of 5-HT1A, 5-HT2A, dopamine D1, D5, and D2, D4 receptors in primate PFC and their 
possible functions in the neuronal circuits of the prefrontal cortex. 
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Prefrontal cortex: location, connectivity and cytoarchitecture 
In mammals the PFC is located in the anterior part of the frontal lobe, anterior to 
the motor and premotor cortical areas. It is traditionally divided into three major 
regions: orbitofrontal and ventromedial areas, dorsolateral prefrontal cortex, and the 
anterior and ventral cingulate cortex. The PFC comprises areas 8-13, 24, 25, 32, and 
44-47 according to Brodmann (Brodmann and Garey 2006). The dorsal PFC refers to 
Brodmann’s area (BA) 8, 9 and 10; the dorsolateral PFC to BA 46 and ventral to 
BA9; the lateral PFC to BA 44, 45, 47; the orbitofrontal PFC to areas BA 11, 12; the 
anterior cingulate region to BA 24 and 25, and the cortex of the medial surface to BA 
32 (Fallon et al. 2003). The PFC is described as a six-layered structure, as other 
neocortical regions, and it is distinguished by a granular layer IV (see Figure 1). 
In primates the PFC orchestrates thoughts and actions, as well as the planning of 
complex cognitive and affective functions, and it is therefore implicated in mood 
disorders (Ebert and Ebmeier 1996). The orbital and medial regions are involved in 
the control of emotional behavior, whereas the lateral regions, which are highly 
developed in humans, provide cognitive support to the temporal organization of 
behavior, speech, reasoning and the execution of complex behaviors that require 
working memory, as already mentioned; for reviews see (Cavada et al. 2000; Elston 
2003; Fuster 1997; Goldman-Rakic et al. 1984).  
The PFC receives projections from the amygdala (Barbas and de Olmos 1990), 
the ventral striatum (Kunishio and Haber 1994) and thalamus (Barbas et al. 1991). 
Specifically, it receives dopaminergic efferents from the ventral tegmental area (VTA) 
(Berger et al. 1988; Conde et al. 1995; Lindvall et al. 1978) and serotonergic 
innervation from the median and dorsal raphe nuclei (Berger et al. 1988; Smiley and 
Goldman-Rakic 1996b), while it sends glutamatergic projections to both the VTA and 
the nucleus accumbens (Sesack and Pickel 1992; Taber et al. 1995), as well as to 
the raphe nuclei (Sesack et al. 1989). The PFC is connected with other association 
cortices but not with primary sensory or motor cortices. There is an important internal 
network of connectivity between the different divisions of the PFC; indeed, each of 
the three major prefrontal regions (orbital, medial and lateral) is connected with itself 
and with the other two. Some of the cortico-cortical connectivity of the PFC is 
interhemispheric and the majority is organized in a reciprocal and topographical 
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manner (Cavada and Goldman-Rakic 1989a; 1989b). These cortico-cortical 
connections originate and terminate in upper cortical layers II and III (Andersen et al. 
1985). 
As in other cortical regions, there are two main cell types in the PFC. One is the 
pyramidal and spiny stellate cells characterized by the excitatory asymmetric 
synapses which they form (glutamatergic). The majority of cortical neurons are 
pyramidal output neurons, found mainly in layers II-VI. The others are smooth or 
sparsely spiny neurons, which are interneurons that form inhibitory symmetric 
synapses (GABAergic) and are found in layers I-VI. In the cerebral cortex several 
different subclasses of GABA-containing neurons can be distinguished by their 
content of calcium-binding proteins and electrophysiological characteristics: 
parvalbumin (PV) cells with physiological properties of fast-spiking interneurons and 
the morphology of chandelier and large basket cells; and calbindin (CB) cells with 
physiological properties of non-fast-spiking interneurons, the majority of which show 
the morphology of double-bouquet cells (Conde et al. 1994; DeFelipe 1997; Zaitsev 
et al. 2005).  
Specific populations of PFC pyramidal neurons have been proposed to be 
responsible for maintaining “on-line” the information required for working memory 
(Goldman-Rakic 1995). Furthermore, inhibitory neurons in the PFC seem to play an 
important role in regulating the spatially-tuned activity of pyramidal neurons during 
working memory. As mentioned above, there is also evidence that PFC dysfunction 
is a pathophysiological feature of schizophrenia, and a role has been demonstrated 
for GABAergic interneurons in the regulation of PFC function (Goldman-Rakic and 
Selemon 1997; Lewis et al. 1999). Reduced expression for GAD67 (67 kDa isoform 
of glutamate decarboxylase), a synthesizing enzyme for GABA, has been found in 
the dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia (Volk et 
al. 2000) but only in a subset of these GABAergic neurons, the parvalbumin-positive 
neurons (Beasley et al. 2002; Daviss and Lewis 1995; Hashimoto et al. 2003), which 
also had reduced but detectable levels of parvalbumin mRNA. Thus, the number of 
PV-expressing GABA neurons in the DLPFC of subjects with schizophrenia is 
unchanged, but they do have decreased expression of several genes, thus impairing 
cell function.  
The major treatment for schizophrenia is antipsychotic or neuroleptic drugs, all of 
which are characterized by their ability to interact with dopaminergic and serotonergic 
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neurons. They are usually divided into two classes, called typical and atypical 
neuroleptics, differentiated by their profiles of unwanted side-effects. Additionally, the 
effects of these drugs on cognitive parameters in the disease are limited. In this 
regard, the need to develop new and more efficacious neuroleptics highlights the 
need to understand the cellular location of the sites of action of these drugs. 
An important element in the chemical machinery of the brain is neurotransmitter 
receptors. Receptors for certain neurotransmitters, such as dopamine and serotonin, 
are relevant because they are the sites of action for drugs used in the treatment of 
psychiatric disorders. In this paper we review recent data on the cellular localization 
of specific subtypes of these receptors in the primate prefrontal cortex with the goal 
of integrating this information on the molecular circuitry of this brain area and its 
relevance, thus laying the basis for the development of drugs to improve psychiatric 
disorders. The review covers recent data from our laboratory and others on the 
cellular localization of 5-HT1A, 5-HT2A, dopamine D1, D5, and D2, D4 in primate PFC. 
In these studies we have used double in situ hybridization approaches, which enable 
the expression of receptors to be correlated with the expression of molecules that 
define the cellular phenotype. These results are analyzed together with data on 
radioligand binding autoradiography and immunohistochemistry using receptor 
antibodies in order to propose the localization of receptors and their possible 
functions in the neuronal circuits of the PFC. Table 1 summarizes current knowledge 
on the laminar and cellular localization of these receptors. 
 
 
5-HT receptors in the monkey PFC 
The PFC receives serotonergic innervation from the medial and dorsal raphe 
nuclei (Mamounas et al. 1991; Steinbusch 1981; Wilson and Molliver 1991a;  1991b). 
Serotonergic axons are present in all PFC layers, presenting a slight reduction in 
their density in layer III (Wilson and Molliver 1991a), with beaded axons 
predominating in layer I and fine axons in layers II-VI. The serotonergic neurons 
synapse primarily on GABAergic interneurons (Smiley and Goldman-Rakic 1996a). 
The raphe nuclei receive reciprocal glutamatergic innervation from the PFC (Sesack 
et al. 1989).  
The action of 5-HT in these cells can be mediated by serotonin receptors. There 
are seven subtypes of 5-HT receptors, which, together with their different subtypes 
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result in at least fourteen different receptors, plus the many subtypes that result from 
alternative splicing (Hoyer et al. 2002). The involvement of serotonin in schizophrenia 
has been a subject of much interest (Breier 1995) due to the particular 
pharmacological profile exhibited by atypical antipsychotic drugs such as clozapine, 
olanzapine and quetiapine, which are potent 5-HT2A receptor antagonists and 
relatively weaker dopamine D2 receptor antagonists (Meltzer 1999). Of the remaining 
5-HT receptors with which these drugs also interact, 5-HT1A receptors have been 
postulated as additional good receptor candidates for their contribution to the 
antipsychotic action of these drugs. However, in contrast with 5-HT2A receptors, 
where blockade is required for therapeutic activity, the stimulation of 5-HT1A 
receptors appears to produce similar effects to the antagonism of 5-HT2A receptors 
(Meltzer 1999).  
The involvement of serotonin in the pathophysiology of schizophrenia is supported 
by the clinical efficacy of drugs acting on 5-HT receptors. Additionally, in attempts to 
pinpoint specific brain regions and cells involved in the clinical activity of these drugs 
a number of studies have examined the changes in postmortem brain tissue from 
schizophrenic patients. Changes in 5-HT receptor densities have been described in 
different brain areas. For example, 5-HT1A receptors have been found to have 
increased densities in the prefrontal cortex of schizophrenic patients (Hashimoto et 
al. 1993; Sumiyoshi et al. 1996), whereas for 5-HT2A receptors the findings are less 
consistent since both increments (Joyce et al. 1993) and reduction (Dean et al. 1998) 
have been described in this brain area. The levels of mRNA coding for 5-HT2A 
receptors are lower in PFC of schizophrenic patients (Burnet et al. 1996). They 
remained unchanged in patients treated with neuroleptics and dropped when patients 
had been free of neuroleptics for more than six months (Hernandez and Sokolov 
2000).  
We will now review the recent data from our laboratory and others on the cellular 
localization of 5-HT1A and 5-HT2A receptors in PFC. 
 
Cellular localization of 5-HT1A in PFC 
The 5-HT1A receptor is negatively coupled to adenylate cyclase through the G 
protein Gi/o. This receptor can be considered as having the opposite functional effect 
to the 5-HT2A receptor. Activation of the inhibitory 5-HT1A autoreceptor on the raphe 
nucleus cells attenuates the firing of these neurons. 
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5-HT1A receptors are found at high densities in the PFC of many species 
(Marazziti et al. 1994; Pazos et al. 1987a; Pazos and Palacios 1985; Pompeiano et 
al. 1992), preferentially in external cortical layers (Mengod et al. 1996). 
Immunohistochemical and in situ hybridization studies have revealed the presence of 
5-HT1A receptor protein and mRNA in external PFC layers in rat (Abbas et al. 2007; 
Kia et al. 1996; Pompeiano et al. 1992; Santana et al. 2004) and in monkey and 
human brain (Burnet et al. 1995; Cruz et al. 2004; DeFelipe et al. 2001; Marazziti et 
al. 1994; Mengod et al. 1996; Pasqualetti et al. 1996). 
There is controversy as to the subcellular location of 5-HT1A receptors. Riad and 
coworkers (Riad et al. 2000) found a somatodendritic location of the receptor protein 
in rat brain. However, by using a different receptor antibody (Azmitia et al. 1996), 5-
HT1A receptor protein has also been localized in axons of pyramidal cells in rat, 
monkey and human (Cruz et al. 2004; DeFelipe et al. 2001). In the rat PFC 60% of 
the glutamatergic cells express 5-HT1A receptors and 25% of the GABAergic 
interneurons contain this receptor mRNA (Santana et al. 2004). Using dual in situ 
hybridization we found that in monkey PFC the percentage of glutamatergic cells 
containing 5-HT1A receptor mRNA is higher than in rat, with 5-HT1A receptor mRNA 
being expressed in about 80% of glutamatergic neurons in external layers II and 
upper III, and in around 50% in layer VI; they are also present in approximately 20% 
of GABAergic neurons (de Almeida and Mengod, submitted). An example of this 
distribution is shown in Figure 2. 5-HT1A receptor transcripts are abundantly 
expressed mainly in layer II and upper III, whereas they are less abundant in the cells 
of layers VI and show very low expression in layers III-V in both species. No 5-HT1A 
receptor mRNA hybridization signal was seen in layer I. A notable co-localization of 
5-HT1A receptor mRNA with the glutamatergic marker vGluT1 mRNA, as determined 
by double in situ hybridization histochemistry, can be appreciated in layer II-upper III 
in monkey PFC (see Figure 2B), which contrasts with the lower co-localization of 5-
HT1A receptor mRNA and GAD65/67 mRNA (Figure 2C). 
These results suggest that the binding sites localized by autoradiography 
correspond to those receptors visualized by both immunohistochemistry and in situ 
hybridization, due to the well known somatodendritic localization of these receptors. 
These data point to the pyramidal cells of layer II-III as being one of the main cells in 
PFC that expresses 5-HT1A receptors. Since these cells are known to be involved in 
cortico-cortical projections, both contralateral and ipsilateral, it would seem that these 
receptors play a role in these connections. 5-HT1A receptors are also found in 
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GABAergic cells, although in a lower number of cells, thus providing a second way of 
influencing the role of 5HT in pyramidal and GABAergic cells.  
Cellular localization of 5-HT2A in PFC 
The 5-HT2A receptor activates phospholipase C by coupling to G proteins. As 
mentioned above, this receptor can be considered as having the opposite functional 
effect to the 5-HT1A receptor. 
5-HT2A receptors are found at high densities in the PFC of many species (López-
Giménez et al. 2001; Pazos et al. 1985; Pazos et al. 1987b; Pompeiano et al. 1994). 
In monkey PFC, layers I and III-IV presented the highest densities of 5-HT2A labeled 
receptors (López-Giménez et al. 2001). Immunohistochemical and in situ  
hybridization studies have revealed the presence of 5-HT2A receptors in both rat 
(Cornea-Hebert et al. 1999; Martin-Ruiz et al. 2001; Pompeiano et al. 1994; Willins et 
al. 1997; Xu and Pandey 2000) and monkey and human (de Almeida and Mengod 
2007; Jakab and Goldman-Rakic 1998;  2000; López-Giménez et al. 2001) PFC. 
Layers III and IV showed the highest hybridization levels in monkey PFC (de Almeida 
and Mengod 2007; López-Giménez et al. 2001), although Burnet and coworkers 
observed that 5-HT2A mRNA was concentrated in two bands, probably corresponding 
to lamina III and V (Burnet et al. 1995) in the orbitofrontal cortex. 
Whereas the pyramidal neuron is the major cortical cell type expressing 5-HT2A 
receptors, some cortical GABAergic interneurons have also been found to express 
these receptors in the rat (Santana et al. 2004; Willins et al. 1997) and primate brain 
(Burnet et al. 1995; de Almeida and Mengod 2007; Jakab and Goldman-Rakic 1998). 
Several groups have shown that the PFC 5-HT2A receptor protein is localized in the 
apical dendrites of pyramidal cells (Jakab and Goldman-Rakic 1998; Willins et al. 
1997). In PFC interneurons 5-HT2A receptor expression is found in calbindin positive 
cells (Jakab and Goldman-Rakic 1998). Figure 2D shows that 5-HT2A receptor 
transcripts are abundantly expressed in the monkey prefrontal cortex in a large 
number of cells that are distributed preferentially between layers III and V, whereas 
they are less abundant in the cells of layers II and VI and absent in layer I. It is worth 
mentioning that the largest amount of 5-HT2A receptor mRNA is found in layer V. 
Glutamatergic neurons labeled by a dark precipitate are found in all layers, except 
layer I (Fig. 2E). PFC cells expressing both GABAergic cell markers, GAD65 and 
GAD67, are found scattered throughout the prefrontal cortex, including layer I (Fig. 
2F). The great majority of glutamatergic cells in layers II-V expressed 5-HT2A 
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receptors in the nine prefrontal areas examined (86-100%), with a maximum (almost 
100%) observed in layers III and V. In GABAergic cells in layers II-V, this percentage 
was lower (13-31%). This difference in the percentage of the two cellular populations 
was, however, much lower when layer VI was analyzed. The proportion of 
glutamatergic cells expressing 5-HT2A receptors decreased to 52-72%, whereas 
GABAergic interneurons expressing this receptor increased to 28-46%. This receptor 
is expressed in 45-69% of parvalbumin and in 61-87% of calbindin positive cells (de 
Almeida and Mengod 2007). 
This cellular location, in pyramidal cells of layers III and V, suggests that these 
receptors are involved in cortico-cortical contralateral and ipsilateral connections.  
 
Dopamine receptors 
Dopamine has been associated with functions such as motivation, affect, reward, 
movement, and performance on cognitive tasks. Cognitive symptoms have been 
linked with dopamine dysregulation in several diseases, including schizophrenia 
(Knable and Weinberger 1997).  
The dopaminergic system arises from cells located in the midbrain. Anatomical 
studies in rodents demonstrate that afferents from the PFC innervate the VTA 
GABAergic cells which, in turn, project to the nucleus accumbens (Hurley et al. 1991; 
Sesack et al. 1989; Sesack and Pickel 1992) and the VTA DA cells that project back 
to the PFC (Carr and Sesack 2000) (mesocortical projections). Dopaminergic 
neurons synapse on at least two cellular populations: pyramidal excitatory neurons 
(glutamate) and non-pyramidal GABA interneurons (Cowan et al. 1994; Goldman-
Rakic et al. 1989; Sesack et al. 1995).  
The central actions of dopamine are mediated by dopamine receptors, which are 
classified into D1-like or D2-like receptors based on their pharmacological or 
functional profile (Kebabian and Calne 1979; Missale et al. 1998; Vallone et al. 
2000). Receptors belonging to the D1 family (D1 and D5) are positively linked to 
adenylyl cyclase, whereas those belonging to the D2 family (D2, D3 and D4) are 
negatively coupled to adenylyl cyclase or to other transduction pathways.  
The pharmacological differences between D1-like and D2-like receptors described 
almost thirty years ago (Kebabian and Calne 1979) remain valid today. The number 
of purely selective ligands for each receptor is very limited (Alexander et al. 2004). 
Most of the work done on dopamine receptors has been centred on subcortical 
 10 
regions such as the striatum, where the density of these receptors is very high 
(Camps et al. 1989; Cortés et al. 1989; Palacios et al. 1988). Since it was first 
discovered in the 1970s that the effects of many antipsychotic drugs correlated with 
their affinities to D2 receptors (Creese et al. 1976) most of the research on the 
aetiology and treatment of schizophrenia has been centred on these receptors. 
Subsequently, and given the involvement of cortex and particularly the PFC in 
schizophrenia (Weinberger 1988), the study of the expression of dopamine receptors 
in this brain area has become an important issue.  
 
Cellular localization of D1-like receptors in the PFC 
Dopamine binds to D5 receptors with a 5-10 fold higher affinity than for D1 
receptors (Sunahara et al. 1991). As there are no pharmacological tools capable of 
differentiating between D1 and D5 receptors the pharmacological effects of D1 
agonists are likely to be mediated by both D1 and D5 receptors. The only way to 
functionally dissect these two receptor subtypes is by knock out mice and antisense 
strategies (Sibley 1999). The D1 family of dopamine receptors are very abundant in 
the neocortex (Cortés et al. 1989). Receptor autoradiography studies with D1 specific 
ligands have demonstrated that D1-like receptors are present in both human (Cortés 
et al. 1989) and monkey neocortex at high densities in superficial layers I-IIIa and in 
deep layers V-VI, as well as at lower densities in layers IIIb-IV (Lidow et al. 1991). 
High hybridization levels for D1 and D5 receptor mRNAs have been described in 
the primate neocortex (Huntley et al. 1992; Meador-Woodruff et al. 1996). In human 
prefrontal cortex Meador-Woodruff et al. (Meador-Woodruff et al. 1996) described the 
presence of D1 mRNA receptors in the deeper layers, with faint labeling in more 
superficial layers. In situ hybridization studies to examine the expression of D1 and 
D5 receptor mRNAs in PFC showed their presence primarily in cell layer V in both 
human and non-human primates (Lidow et al. 1998). In monkey PFC, D1 mRNA can 
also be found in layer II and part of layer VI in addition to layer V, whereas D5 mRNA 
is found exclusively in layer V (de Almeida and Mengod, in preparation) (see Fig. 3). 
D1-like immunoreactivity is present in cortical interneurons of monkey, it being 
prevalent in parvalbumin-containing neurons and less common in calretinin-
containing interneurons (Muly et al. 1998). However, by using another antibody 
Paspalas and coworkers were unable to detect any D1-immunoreaction in 
parvalbumin-positive cells in monkey PFC (Paspalas and Goldman-Rakic 2005). In 
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monkey PFC, D1-like immunoreactivity is found preferentially in the distal dendrites 
and spines of pyramidal cells, as well as on the dendrites and axon terminals of 
putative GABAergic interneurons (Bergson et al. 1995b; Muly et al. 1998; Smiley et 
al. 1994), whereas D5 receptors are located on perikarya and proximal dendrites of 
many pyramidal and some non-pyramidal neurons (Bergson et al. 1995a; Bergson et 
al. 1995b; Ciliax et al. 2000; Khan et al. 2000) in layers IV-VI. D1 immunoreactivity 
for the heteroreceptor is distinctly localized on perisynaptic and extrasynaptic 
membranes of excitatory-like varicosities (Paspalas and Goldman-Rakic 2005). 
  
Cellular localization of D2-like receptors in the PFC 
The distribution of D2-like receptors in the monkey and human brain has been 
analyzed by receptor radioligand autoradiography (Camps et al. 1989; Goldman-
Rakic et al. 1989; Lidow et al. 1989; Mengod et al. 1992). 
In human prefrontal cortex Meador-Woodruff et al. (1996) described the faint 
presence of D2 mRNA receptors in both superficial and deep layers of the PFC. The 
D4 mRNA receptor is more abundant and was found to be expressed in the deeper 
layers with faint labeling in more superficial layers, there being an apparent 
enrichment in the deep cortex. The same authors comment that the expression of D3 
and D5 receptor mRNAs in PFC is particularly rare and they appear to be expressed 
in the deeper layers. In monkey PFC the mRNA coding for D2, D3 and D4 receptor 
subtypes is present in all the cellular layers but is especially abundant in layer V 
(Lidow et al. 1998). Work in progress in our laboratory shows that in monkey PFC D2 
mRNA is found exclusively in layer V, whereas D4 mRNA can also be found in 
almost all layers (except in layer I) and at high levels in layer V (de Almeida and 
Mengod, in preparation) (see Fig. 3). 
D4 immunoreactivity has been detected in both pyramidal and non-pyramidal cells 
of human cortical areas including prefrontal cortex (Khan et al. 1998a), whereas D2 
and D3 immunostaining was found to be mostly associated with non-pyramidal 
neurons (Khan et al. 1998a; 1998b). About 60% of cortical interneurons showed 
labeling in soma and dendritic shafts (Khan et al. 2001), while a subset (40%) of 
these showed immunolabeling in astrocytic processes enwrapping the cell bodies. 
These authors estimate that approximately 35% of the total D2 receptor binding 
activity in the cortex may be associated with astrocytes. In primate brain the D4 
receptor antibody labeled GABAergic neurons in cerebral cortex, some of which were 
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parvalbumin (Mrzljak et al. 1996). D2 receptor IR is localized in distal dendritic and 
axonal processes (Negyessy and Goldman-Rakic 2005).  
 
Interaction of 5-HT, dopamine and their receptors: involvement in 
schizophrenia 
The successful therapeutic application of antypsychotics, such as clozapine, 
olanzapine, seroquel and sertindole, has focussed much research attention on 
understanding the interaction between the serotonergic and dopaminergic systems. 
As one of the characteristics of these compounds is their ability to block both 
dopamine and serotonin receptors, the initial focus has been on dopamine D2 and 
5HT2 receptors (Meltzer et al. 1989). More recently, the efficacy and tolerability of the 
“atypical” antipsychotic drugs is attributed in part to their interaction with specific 
serotonin receptors such as 5-HT1A and 5-HT2A.  
At the neuroanatomical level the interaction between 5-HT and DA mechanisms 
has been analyzed in different pathways. Serotonin from the dorsal raphe inhibits the 
firing of dopaminergic neurons in the substantia nigra and antagonizes dopamine-
mediated behaviors. This action is modulated by 5-HT2 receptors located in the 
dopaminergic neurons. The raphe also projects to the striatum and the release of 5-
HT is also associated with an inhibition of striatal neuronal firing. In addition, 
serotonergic influence on striatal cholinergic and GABAergic systems is also well 
documented (see (Alex and Pehek 2007; Kapur and Remington 1996; Werkman et 
al. 2006). Again, the role of 5-HT2 receptors in mediating the inhibitory effects of 
serotonin on dopaminergic activity is well documented. Additionally, 5HT1A agonists 
have also been found to reverse catalepsy in rodents and extrapyramidal symptoms 
in primate models by acting on the firing of serotonergic neurons, suggesting that the 
combination of 5-HT1A agonist and D2 antagonist could result in an improved 
antipsychotic profile (Meltzer et al. 2003; Newman-Tancredi et al. 2005). While most 
studies have focused on dopaminergic transmission, understanding the serotonin-
dopaminergic interactions involved in the mechanism of action of neuroleptics will 
require a different viewpoint as regards the situation in the cortex.  
The PFC is the most appropriate region in which to look for interactions between 
dopamine and serotonin through their cortical receptors, located either in pyramidal 
cells or GABAergic interneurons. For example, it has been shown that the increase in 
prefrontal cortex dopamine release produced by atypical antipsychotics such as 
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clozapine, olanzapine and ziprasidone, but not by haloperidol, seems to involve 5-
HT1A receptor activation (Diaz-Mataix et al. 2005; Ichikawa et al. 2001). 5-HT1A 
receptor agonists increase dopamine release in PFC, suggesting that this is a 
potential basis for the action of at least some of the atypical antypsychotics (Rollema 
et al. 1997; Sakaue et al. 2000). 
The role of the cortical glutamatergic pyramidal neuron is to integrate thousands of 
afferent inputs from GABAergic interneurons, as well as from serotonergic and 
dopaminergic fibres, and also to control movement and affect through its efferent 
projection (Goldman-Rakic et al. 2000). Dopamine axons represent a significant 
source of afferentation of PFC in primates (Williams and Goldman-Rakic 1993;  
1998), with area 9 being the one having the greatest density of dopaminergic fibres. 
Dopaminergic innervation in PFC reveals, in general, a bilaminar pattern of 
distribution that is especially dense in layer I and less so in layer II, with intermediate 
density being observed in layers V and VI (Lewis 1992). The PFC in primates also 
receives serotonergic innervation from the medial and dorsal raphe nuclei (Wilson 
and Molliver 1991a;  1991b). 5-HT axon fibres are found in a moderate density in all 
layers in monkey DLPFC (Wilson and Molliver 1991a). DeFelipe and coworkers ( 
2001) found a distinct density of 5-HT fibres in supragranular layers (I-III) and a much 
lower one in infragranular layers. The serotonergic neurons from the raphe nuclei 
synapse primarily on GABAergic interneurons (Smiley and Goldman-Rakic 1996a). 
The raphe nuclei receive reciprocal glutamatergic innervation from the pyramidal 
cells of PFC (Sesack et al. 1989).  
The laminar distribution of cell bodies expressing 5-HT1A and 5-HT2A receptors 
shows a “complementary” pattern, since 5-HT1A receptors are mainly found in 
superficial layers II and part of III and at lower levels in deep layer VI, whereas 5-
HT2A receptors are located in intermediate layers III-V. This distribution could be 
related in part with the presence of different types of 5-HT axons (Raghanti et al. 
2008; Wilson and Molliver 1991a), as discussed above. The these two 5-HT 
receptors are present in most PFC pyramidal neurons, where they could probably be 
co-expressed in some cells, while only a low proportion of cortical GABAergic cells 
express either receptor. Pyramidal 5-HT2A receptors can modulate excitatory 
glutamate inputs (Puig et al. 2003), whereas 5-HT1A receptors could act by reducing 
glutamate release in the thalamus. 
 14 
All dopamine receptors are found to be expressed in PFC layer V (Lidow et al. 
1998); additionally, D1 and D4 are found in other PFC layers in monkey (de Almeida 
and Mengod, in preparation), except in layer I. The observation that schizophrenia is 
associated with an altered dopamine innervation of PFC area 9, which is lamina- and 
neurotransmitter specific (Akil et al. 1999), indicates the importance of understanding 
the laminar (and subsequently, cell type) distribution of both 5-HT and DA receptors.  
In nonhuman primates it has been established that members of the D1-like 
receptor subfamily modulate excitatory transmission in prefrontal microcircuits, 
generating stimulus-independent activity that is essential for working memory 
(Williams and Goldman-Rakic 1995); furthermore, although the cellular basis is 
unknown it is thought to involve D1-like receptor modulation of pyramidal neuron 
excitability in a layer- and input-specific manner (see Seamans and Yang, 2004) 
(Seamans and Yang 2004).  
The coexpression of dopamine and serotonin receptors in the same PFC cells has 
not yet been analyzed in any species. However, the only cortical layer where this 
could occur is layer V (see Table 1), where most of these receptors, with the 
exception of 5-HT1A, are present. Greater knowledge about this aspect could 
therefore help in understanding the array of electrophysiological data concerning the 
actions of antipsychotic drugs in PFC.  
Conclusions 
In conclusion, we have reviewed the current neuroanatomical data regarding a 
role for dopamine and serotonin in the functions of primate PFC through different 
receptor subtypes, namely 5-HT1A, 5-HT2A, D1, D2, D4 and D5, which are expressed 
in this brain area. The specific cellular populations expressing these receptors have 
been identified using in situ hybridization techniques.  
One of the major findings of these studies is the non-overlapping localization of 5-
HT1A, 5-HT2A  receptors in the primate PFC with regards to their laminar localization 
and the involvement of cortical circuitry and projections. This suggests 
complementary rather than redundant roles for these receptors in regulating 
functions of the PFC, in addition to their excitatory or inhibitory nature. 
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Figure legends 
 
Fig 1. The prefrontal cortex is a group of cortical areas located in the anterior part of 
the frontal lobe (upper panel) of the monkey brain. A coronal section of monkey PFC 
stained with cresyl violet shows the main divisions: orbital, ventromedial and 
dorsolateral, as well as some of the Brodmann areas. The small rectangle of area 46 
is shown in the right at higher magnification, where the six laminae are numbered 
from the pial surface to the white matter, based on the density and the size of the 
cresyl violet stained cells. 
 
Figure 2. Autoradiographic localization of mRNAs coding for 5-HT1A (a) and 5-HT2A 
(b) receptor mRNAs in monkey prefrontal cortex. Cellular localization of 5-HT1A (c, e) 
and 5-HT2A (d, f) receptor mRNAs in glutamatergic (c, d) and GABAergic (e, f) cell 
populations in monkey PFC. High-magnification bright-field microphotographs of 
emulsion-dipped sections of layer II-upper III of the dorsolateral prefrontal cortex, 
simultaneously showing the different mRNAs visualized by double in situ 
hybridization using 33P-labeled oligonucleotides complementary to the mRNA coding 
for serotonin receptors 5-HT1A and 5-HT2A (clusters of dark silver grains), with DIG-
labeled oligonucleotides (dark precipitate) for vGluT1 mRNA (glutamatergic cells), 
panels c and d, or for GAD65/67 mRNA (GABAergic cells), panels e and f. The white 
arrow head indicates a radioactively-labeled cell, the grey arrow head points to DIG-
labeled cells and the red arrow head to a double-labeled cell. Bars=3 mm (a, b), 30 
µm (c-f).  
 
 
Figure 3. Autoradiographic localization of mRNAs coding for D1, D5, D2, and D4 
receptor mRNAs in monkey prefrontal cortex. D1 mRNA is found in layers II, III, V 
and VI. D5 and D2 mRNAs are found in layer V. D4 mRNA is present in layers II-VI, 
and is especially abundant in layer V. Bar=5 mm. 
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Table 1. Layer and Cellular localization of dopamine and serotonin receptors in primate prefrontal cortex 
 
 
    Receptor     
  D1 D5 D2 D3 D4 5-HT1A 5-HT2A 
Layers         
 Receptor 
Autoradiography 
I,II, V1 
I-IIIa, V-VI2 nd 
I,II, upper III3 
V2 nd nd 
Superficial 
layers4 I, III-IV
5,6 
 Receptor 
Immunoreaction II, III, V
7 II, III, V
7 
IV-VI8 IV-V
9 IV-V9 IV-V9 II-upper III10 II, III, V, VI11 
 
Receptor mRNA 
Deep layers12 
V13 
II,III,V,VI14 
Deep layers*12 
V13,14 
Superficial and 
deep layers*12 
V13,14 
Deep 
layers*12 
V13 
Superficial and 
deep layers12 
V13 
III-V15 
II-VI14 
Superficial 
layers4,16,17 
III, V16 
III-IV5,6 
Cell type Pyramidal cells +7 +7,8 +9 nd +9,15 +16,17 +6,11,16 
 GABAergic cells +7 +7 +9 +9 +9,15 +17 +6,11,16 
 parvalbumin +19 nd nd nd nd nd +6 
 calbindin nd nd nd nd nd nd +6,11 
 calretinin +/-18 nd nd nd nd nd nd 
* faint expression 
 
1 Cortés et al. (1989). 2 Lidow et al. (1991). 3 Camps et al. (1989). 4  Mengod et al. (1996). 5 López-Giménez et al. (2001). 6 de Almeida and Mengod (2007). 7 Bergson et al. 
(1995). 8 Khan et al. (2000). 9 Khan et al. (1998). 10 DeFelipe et al. (2001). 11 Jakab and Goldman-Rakic (1998). 12 Meador-Woodruff et al. (1996). 13 Lidow et al. (1998). 14 de 
Almeida and Mengod (in preparation). 15 Mrzljak et al. (1996). 16 Burnet et al. (1995). 17de Almeida and Mengod G. (submitted).  18 Muly et al. (1998). 
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